Tonix Pharmaceuticals

OverviewSuggest Edit

Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

TypePublic
Founded2007
HQNew York, US
Websitetonixpharma.com
Employee Ratings4

Latest Updates

Employees (est.) (Mar 2019)12(-14%)
Share Price (May 2019)$2 (+19%)

Key People/Management at Tonix Pharmaceuticals

Seth Lederman

Seth Lederman

Co-Founder, CEO & Chairman
Jessica Edgar Morris

Jessica Edgar Morris

COO
Gregory Sullivan

Gregory Sullivan

Chief Medical Officer
Bradley Saenger

Bradley Saenger

CFO
Show more

Tonix Pharmaceuticals Office Locations

Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin
New York, US (HQ)
509 Madison Ave
San Diego, US
4225 Executive Square #250, La Jolla
Montréal, CA
317 1176 Rue Bishop
Dublin, IE
65 Adelaide Rd
Show all (4)

Tonix Pharmaceuticals Financials and Metrics

Tonix Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(26.1m)

EBIT (FY, 2018)

(26.3m)

Market capitalization (22-May-2019)

12.4m

Closing stock price (22-May-2019)

2.0

Cash (31-Dec-2018)

25.0m
Tonix Pharmaceuticals's current market capitalization is $12.4 m.
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

4.1m6.2m12.7m10.4m7.9m8.8m

R&D expense

2.6m4.7m35.5m28.5m13.3m17.6m

Operating expense total

6.7m10.9m48.2m39.0m21.3m26.3m

EBIT

(6.7m)(10.9m)(48.2m)(39.0m)(21.3m)(26.3m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.0m2.2m2.9m2.9m3.0m3.3m2.3m2.1m2.1m1.9m1.8m3.9m

R&D expense

4.1m5.2m6.8m8.9m10.3m10.7m7.5m5.5m3.0m3.9m5.2m9.2m

Operating expense total

6.0m7.4m9.7m11.8m13.3m14.0m9.8m7.6m5.1m5.8m7.0m13.1m

EBIT

(6.0m)(7.4m)(9.7m)(11.8m)(13.3m)(14.0m)(9.8m)(7.6m)(5.1m)(5.8m)(7.0m)(13.1m)
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.8m8.2m19.2m18.9m25.5m25.0m

Accounts Receivable

598.6m

Current Assets

2.0m8.6m46.4m27.1m26.4m26.1m

PP&E

350.0k150.0k91.0k43.0k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m29.3m19.3m16.7m

Current Assets

44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m30.2m20.7m18.2m

PP&E

306.0k316.0k327.0k383.0k349.0k315.0k132.0k102.0k78.0k65.0k

Total Assets

45.1m47.3m60.5m50.9m57.8m31.3m34.3m29.8m23.8m30.5m21.0m18.4m
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(9.4m)(10.9m)(48.1m)(38.8m)(21.1m)(26.1m)

Depreciation and Amortization

14.3k17.0k161.0k206.0k70.0k54.0k

Accounts Payable

130.6k(60.0k)1.6m(2.2m)424.0k106.0k

Cash From Operating Activities

(5.7m)(8.5m)(42.5m)(37.3m)(19.1m)(24.0m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(6.0m)(7.4m)(9.7m)(11.8m)(13.2m)(14.0m)(9.8m)(31.4m)(5.1m)(15.6m)(6.9m)(13.0m)

Depreciation and Amortization

163.0k50.0k15.0k30.0k

Accounts Payable

2.0m2.8m2.4m2.1m1.9m(2.1m)841.0k490.0k(32.0k)342.0k

Cash From Operating Activities

(31.9m)(14.2m)(6.8m)(12.3m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Tonix Pharmaceuticals News and Updates

Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the first annual Second Chance Digital Impact Recipient Gala being held May …

Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting. The…

Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020 Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020

Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)

The Termination Does Not Affect Tonix’s Finances or the Ongoing RECOVERY Trial of Tonmya® for the Treatment of PTSD The Termination Does Not Affect Tonix’s Finances or the Ongoing RECOVERY Trial of Tonmya® for the Treatment of PTSD 

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

Company Will Meet with FDA in June to Address the “Intent to Rescind” Notice Company Will Meet with FDA in June to Address the “Intent to Rescind” Notice

Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'

Tonix Pharmaceuticals Holding Corp. disclosed Friday that the U.S. Army Medical Material Development Activity (USAMMDA) is exercising its right to "terminate without cause" the research and development agreement with the company. The termination of the agreement, which Tonix and USAMMDA entered in …
Show more

Tonix Pharmaceuticals Blogs

Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleas…

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences. Details of the Tonix Pharmaceuticals presentations and webcasts are as follows: Eve…

Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

Topline Data Expected First Half 2020 NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biolo…

Tonix Pharmaceuticals Announces Share Repurchase Program

NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $2 million in value of its outstanding comm…

Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on F…

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019. In additio…
Show more

Tonix Pharmaceuticals Frequently Asked Questions

  • When was Tonix Pharmaceuticals founded?

    Tonix Pharmaceuticals was founded in 2007.

  • Who are Tonix Pharmaceuticals key executives?

    Tonix Pharmaceuticals's key executives are Seth Lederman, Jessica Edgar Morris and Gregory Sullivan.

  • How many employees does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 12 employees.

  • Who are Tonix Pharmaceuticals competitors?

    Competitors of Tonix Pharmaceuticals include Vitality Biopharma, Mylan and Savara Pharmaceuticals.

  • Where is Tonix Pharmaceuticals headquarters?

    Tonix Pharmaceuticals headquarters is located at 509 Madison Ave, New York.

  • Where are Tonix Pharmaceuticals offices?

    Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin.

  • How many offices does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 4 offices.